PRELUDE CAPITAL MANAGEMENT, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 134 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2017. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2017$52,000
-85.1%
18,300
+31.8%
0.01%
-89.8%
Q2 2015$350,000
-9.6%
13,8860.0%0.05%
-9.3%
Q1 2015$387,00013,8860.05%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2017
NameSharesValueWeighting ↓
TSP Capital Management Group, LLC 813,273$3,286,0001.66%
RTW INVESTMENTS, LP 1,243,164$5,022,0001.52%
Marcus Capital, LLC 112,200$453,0000.44%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 996,178$4,024,0000.29%
Benchmark Capital Advisors 67,000$271,0000.20%
SUFFOLK CAPITAL MANAGEMENT LLC 360,299$1,456,0000.20%
COLUMBIA WANGER ASSET MANAGEMENT LLC 2,907,523$11,746,0000.15%
Virtus ETF Advisers LLC 59,537$241,0000.12%
Bellevue Group AG 160,000$646,0000.12%
PDT Partners, LLC 428,300$1,730,0000.10%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders